Insight into the mechanism of action of heparin cofactor II
DM Tollefsen - Thrombosis and haemostasis, 1995 - thieme-connect.com
DM Tollefsen
Thrombosis and haemostasis, 1995•thieme-connect.comThe anticoagulant activities of glycosammoglycans are mediated by antithrombin and
heparin eofaetor II (HCII)(I). When antithronihin is bound to soluble heparin or to heparan
sulfate in the vessel wall, it ra pidly inhibits thrombin, faetor Xa, and factor IXa. HCII inhibits
throm bin, but not other eoagulation proteases, in the presence of heparin or dermatan
sulfate (2, 3). This review will loeus on the biochemistry of HCII, with an emphasis on recent
evidence that HCII and antithrombin inhibit thrombin by fundamentally different mechanisms.
heparin eofaetor II (HCII)(I). When antithronihin is bound to soluble heparin or to heparan
sulfate in the vessel wall, it ra pidly inhibits thrombin, faetor Xa, and factor IXa. HCII inhibits
throm bin, but not other eoagulation proteases, in the presence of heparin or dermatan
sulfate (2, 3). This review will loeus on the biochemistry of HCII, with an emphasis on recent
evidence that HCII and antithrombin inhibit thrombin by fundamentally different mechanisms.
The anticoagulant activities of glycosammoglycans are mediated by antithrombin and heparin eofaetor II (HCII)(I). When antithronihin is bound to soluble heparin or to heparan sulfate in the vessel wall, it ra pidly inhibits thrombin, faetor Xa, and factor IXa. HCII inhibits throm bin, but not other eoagulation proteases, in the presence of heparin or dermatan sulfate (2, 3). This review will loeus on the biochemistry of HCII, with an emphasis on recent evidence that HCII and antithrombin inhibit thrombin by fundamentally different mechanisms.
Thieme Connect